89151-46-2

Basic information

• Product Name: 1-Boc-4-(2-iodoethyl)piperidine
• Synonyms: 1-Boc-4-(2-iodoethyl)piperidine;1-Piperidinecarboxylic acid, 4-(2-iodoethyl)-, 1,1-dimethylethyl ester;1-Boc-4-(2-Iodoethyl)Piperidine(WX630127);TERT-BUTYL 4-(2-IODOETHYL)PIPERIDINE-1-CARBOXYLATE
• CAS NO: 89151-46-2
• Molecular Formula: C₁₂H₂₂INO₂
• Molecular Weight: 339.21305
• Mol File: 89151-46-2.mol
• Article Data: 40

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Boc-4-(2-iodoethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(2-iodoethyl)piperidine(89151-46-2)
• EPA Substance Registry System: 1-Boc-4-(2-iodoethyl)piperidine(89151-46-2)

Safety Data

• Hazardous Substances Data: 89151-46-2(Hazardous Substances Data)

Usage

Molecular weight

386.29 g/mol

Type of compound

Chemical compound

Derivative of

Piperidine (a heterocyclic ring compound)

Common use

Synthesis of pharmaceuticals and agrochemicals

Presence of 1-Boc (tert-butoxycarbonyl) protecting group

Indicates its use as an intermediate in organic synthesis

Role in organic synthesis

Production of other drugs and organic compounds

Addition of 2-iodoethyl group

Provides reactivity towards nucleophilic substitution reactions

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 89151-45-1 tert-butyl-4-(2-(tosyloxy)ethyl)piperidine-1-carboxylate 
• 288-32-4 1H-imidazole 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 98-59-9 p-toluenesulfonyl chloride 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 

Downstream Products

• 301225-86-5 4-(2-((4-fluorophenyl)thio)-1-ethyl)-1-tert-butoxycarbonyl-piperidine 
• 347873-67-0 4-(2-phenoxyethyl)piperidine 
• 252918-94-8 1-(tert-butoxycarbonyl)-4-[2-phenoxyethyl]piperidine 
• 790224-01-0 (R) 4-[2-(2-amino-3-phenyl-propoxy)-ethyl]-piperidine-1-carbamic acid tert-butyl ester 
• 912451-02-6 tert-butyl 4-[2-(4-oxo-2-phenyl-4,5-dihydro-2H-pyrazolo[3,4-c]quinolin-1-yl)ethyl]piperidine-1-carboxylate 
• 163209-93-6 methyl 4-(2-N-BOC-piperidin-4-ylethoxy)benzoate 

Relevant articles and documents

Selective acetylcholinesterase inhibitors derived from muscle relaxant dantrolene

Dantrolene, the only therapeutic agent for malignant hyperthermia, is known to have not only a muscle relaxant effect, but also a neuroprotective effect and Alzheimer's disease improving effect. Recently, it has been reported that dantrolene has a weak inhibitory effect on acetylcholinesterase (AChE), which is a therapeutic drug target for Alzheimer's disease. Thus, we focused on developing of AChE inhibitors with benzylpiperidine/piperazine moieties that are based on the dantrolene skeleton. Several derivatives showed an inhibitory activity. Among them, ortho-nitro derivative 8c showed the most potent inhibitory activity with the IC50 value of 34.2 nM. Furthermore, Lineweaver-Burk plot analysis indicated that 8c is AChE-selective inhibitor, which shows only a weak inhibitory effect on butyrylcholinesterase (BuChE) and a non-competitive inhibition.

ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.

ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.